PMOS symptoms are identical to PCOS symptoms because the underlying condition did not change with the renaming on 12 May 2026. The complete PMOS symptom list spans five pillars: endocrine (high androgens, low SHBG, irregular cycles), metabolic (insulin resistance, weight gain at the waist, fatty liver, pre-diabetes), reproductive (irregular periods, infertility, miscarriage risk), dermatological (acne, hirsutism, hair loss on the scalp, dark patches of skin called acanthosis nigricans), and mental health (3x higher depression, 2.5x higher anxiety, elevated eating disorder risk). Most women with PMOS have symptoms across at least three of the five pillars. The fifth pillar (mental health) is the most under-recognised under the old PCOS framing.
The 5 pillars of PMOS symptoms
The new PMOS name explicitly captures the multi-system nature of the condition. Symptoms organise across five pillars. Most women with PMOS experience symptoms in three or four of the five pillars, not all five.
| Pillar | Most common symptoms | Approx prevalence in PMOS |
|---|---|---|
| Endocrine | High androgens, low SHBG, elevated LH/FSH ratio, mild hyperprolactinemia | 60 to 80% |
| Metabolic | Insulin resistance, weight gain at the waist, pre-diabetes, fatty liver | 50 to 70% |
| Reproductive | Irregular or absent periods, anovulation, infertility, recurrent miscarriage | 70 to 90% |
| Dermatological | Acne, hirsutism, scalp hair thinning, skin tags, dark skin patches | 40 to 70% |
| Mental health | Depression, anxiety, mood swings, eating disorders, sleep disturbance | 30 to 60% |
1. Endocrine symptoms
High androgens (hyperandrogenism)
Most women with PMOS have elevated androgens (testosterone, free testosterone, DHEA-S, or androstenedione). High androgens drive most of the visible PMOS symptoms: acne, hirsutism, scalp hair loss, and oily skin. Around 60 to 80 percent of women with PMOS have clinically elevated androgens on bloodwork.
Low SHBG (sex hormone binding globulin)
SHBG binds testosterone and keeps it inactive. Low SHBG means more free testosterone is available to cause symptoms even when total testosterone looks normal. Low SHBG is also a marker of insulin resistance.
Elevated LH/FSH ratio
The ratio of luteinizing hormone (LH) to follicle stimulating hormone (FSH) is often 2:1 or higher in PMOS, versus around 1:1 in women without. This contributes to irregular cycles and ovulation issues.
Mild hyperprolactinemia
Up to 30 percent of women with PMOS have mildly elevated prolactin. Other causes of high prolactin (pituitary adenoma, hypothyroidism, medications) need to be ruled out first.
2. Metabolic symptoms
Insulin resistance
Around 70 percent of women with PMOS have insulin resistance. Signs that suggest insulin resistance: weight gain at the waist (waist-to-hip ratio above 0.85), fatigue after carb-heavy meals, sugar cravings, difficulty losing weight despite calorie control, dark patches on the back of the neck or under the arms (acanthosis nigricans). Confirmed by fasting insulin (above 10 mIU/L) or HOMA-IR (above 2.0).
Weight gain at the waist
PMOS-related weight gain typically concentrates at the abdomen rather than hips and thighs. This visceral fat is metabolically active and drives further insulin resistance. Around 50 to 80 percent of women with PMOS have a waist circumference above the threshold for metabolic risk (88cm in non-Asian women, 80cm in Asian women).
Pre-diabetes and type 2 diabetes
Women with PMOS are 4 times more likely to develop type 2 diabetes than women without (2023 Lancet meta-analysis of 1.6 million women). Around 30 to 40 percent of women with PMOS have pre-diabetes by age 40, often undiagnosed because routine glucose screening misses post-meal spikes. HbA1c above 5.7 percent or fasting glucose above 5.6 mmol/L (100 mg/dL) signals pre-diabetes.
Non-alcoholic fatty liver disease (NAFLD)
Around 60 percent of women with PMOS have NAFLD per a 2023 systematic review. Often silent in early stages. Detected by elevated ALT or AST on bloodwork or by liver ultrasound. The PMOS renaming makes liver enzyme screening more standard at diagnosis.
Dyslipidaemia
Around half of women with PMOS have one or more lipid abnormalities: high triglycerides, low HDL, or elevated LDL. This contributes to the elevated cardiovascular risk associated with PMOS (roughly 2x lifetime risk versus women without).
3. Reproductive symptoms
Irregular or absent periods
Around 70 to 90 percent of women with PMOS have irregular cycles. Definitions: cycles longer than 35 days, fewer than 8 periods per year, or skipped periods for more than 3 months. The irregularity reflects ovulation that does not happen reliably (anovulation).
Anovulation
Anovulation (the ovary not releasing an egg) is the underlying cause of irregular cycles in PMOS. Confirmed by mid-luteal progesterone testing (day 21 of a 28-day cycle, or 7 days before the next expected period). Persistent anovulation causes infertility and increases endometrial cancer risk over time if untreated.
Infertility
PMOS is the most common cause of female infertility, accounting for around 80 percent of anovulatory infertility. Most women with PMOS can conceive with appropriate management, often with metformin, inositol, weight loss, or ovulation induction (letrozole, clomiphene).
Recurrent miscarriage
Women with PMOS have a roughly 1.5x to 2x higher miscarriage rate than women without, often linked to insulin resistance affecting endometrial receptivity and early embryo support. Improving insulin sensitivity before and during early pregnancy reduces miscarriage rates in observational data.
Endometrial thickening and cancer risk
Persistent anovulation means the endometrium gets unopposed estrogen exposure, which can lead to endometrial hyperplasia and elevates lifetime endometrial cancer risk by roughly 2 to 3 times. Periodic withdrawal bleeds (via progesterone or cyclical OCPs) protect the endometrium in women with very irregular cycles.
4. Dermatological symptoms
Acne
Around 40 percent of women with PMOS have adult acne, typically along the jawline, chin, and neck. Driven by elevated androgens and insulin. Often persists into the 30s and 40s. Responds to dietary intervention, anti-androgen medications (spironolactone), and topical retinoids.
Hirsutism
Excess terminal hair growth in male-pattern areas: chin, upper lip, chest, abdomen, lower back, inner thighs. Around 70 percent of women with PMOS have some degree of hirsutism. Scored using the modified Ferriman-Gallwey scale. Treatment combines hair removal (laser, electrolysis), spironolactone, and dietary intervention.
Scalp hair loss (female pattern hair loss)
Thinning along the central parting, the crown, and at the temples. Around 22 percent of women with PMOS report noticeable scalp hair loss. Driven by androgens and often slow to reverse (12+ months on treatment).
Acanthosis nigricans
Dark velvety patches of skin in folds: back of the neck, armpits, groin, under the breasts. A visible marker of insulin resistance. Affects around 30 percent of women with PMOS and improves as insulin sensitivity improves.
Skin tags
Small soft skin growths on the neck, armpits, or eyelids. Associated with insulin resistance. Common in PMOS and often appear in clusters.
Oily skin and seborrhoea
Driven by androgens. Common in PMOS and improves with anti-androgen therapy or dietary intervention that reduces insulin and free testosterone.
5. Mental health symptoms
This is the pillar the PMOS renaming most clearly reframes. Mental health was inconsistently screened under the PCOS name because depression and anxiety did not fit the "ovary" framing. PMOS makes mental health a recognised pillar.
Depression
Roughly 3 times the rate of depression compared to age-matched women without PMOS, per the 2023 Lancet systematic review. Driven by both biological factors (inflammation, insulin) and psychological factors (body image, fertility distress, symptom burden).
Anxiety
Roughly 2.5 times the rate of anxiety disorders. Generalized anxiety is most common, followed by social anxiety.
Disordered eating and eating disorders
Women with PMOS have a roughly 3x higher rate of binge eating disorder and a 4x higher rate of disordered eating behaviours per a 2022 meta-analysis in Eating Behaviors. The combination of cravings driven by insulin swings and chronic dieting in the pursuit of weight loss contributes.
Sleep disturbance
Insomnia, restless sleep, and obstructive sleep apnoea (around 30x higher risk than women without PMOS for sleep apnoea specifically) are all elevated. Poor sleep worsens insulin resistance, creating a feedback loop.
Mood swings and PMDD
Premenstrual dysphoric disorder (PMDD), severe PMS with mood symptoms, is more common in PMOS. Driven by hormonal swings and amplified by insulin instability.
Symptoms by PMOS phenotype
Although the symptom list is the same condition, the typical symptom cluster differs by phenotype. Recognising your phenotype helps target which symptoms are likely to be most prominent.
| PMOS phenotype | Dominant symptoms | Less prominent |
|---|---|---|
| Insulin-resistant (70%) | Weight gain at waist, fatigue, sugar cravings, fatty liver, acanthosis nigricans, irregular cycles | Severe hirsutism (often milder) |
| Adrenal (15%) | High DHEA-S, stress-driven flares, anxiety, fatigue, mild hirsutism, normal weight | Severe insulin resistance |
| Post-pill (10%) | Acne flare after stopping OCPs, irregular cycles return, scalp hair loss, mood changes | Often resolves within 12 to 18 months |
| Inflammatory (variable) | Severe acne, joint pain, IBS-type digestive symptoms, fatigue, eczema, food sensitivities | Insulin resistance often present but milder |
Take the free 90-second phenotype quiz to find out which phenotype matches your symptom cluster.
Symptoms in adolescents with PMOS
PMOS symptoms in adolescents can be hard to distinguish from normal puberty. The 2023 International Guideline recommends not diagnosing PMOS for at least 3 years after the first period, because cycle irregularity is common in early adolescence and resolves for most girls. Key adolescent symptoms that warrant evaluation: severe acne not responding to standard treatment, hirsutism, persistent cycle irregularity beyond 3 years post-menarche, and weight gain at the waist with insulin resistance markers.
Symptoms in perimenopause with PMOS
PMOS symptoms shift in perimenopause (typically late 30s to mid 40s). Insulin resistance often worsens. Hirsutism may stabilise as androgens decline. Mood symptoms can intensify. Cycles may briefly normalise then become irregular again as menopause approaches. Cardiovascular risk monitoring becomes more important. PMOS does not disappear at menopause; the metabolic risks persist.
When to see a doctor about PMOS symptoms
See a primary care provider, gynaecologist, or endocrinologist if you have any of these:
- Cycles that are consistently longer than 35 days, fewer than 8 per year, or skipped for more than 3 months (not pregnancy-related)
- Persistent acne, especially along the jawline, not responding to standard skincare
- New or progressive hair growth on the face, chest, abdomen, or back
- Scalp hair thinning along the central parting
- Difficulty conceiving after 12 months of trying (6 months if over 35)
- Dark patches of skin on the neck, armpits, or under the breasts
- Weight gain that concentrates at the waist and is resistant to standard calorie control
- Persistent low mood or anxiety, especially around your cycle
The PMOS framing encourages a fuller workup at the first appointment: hormones (testosterone, free testosterone, DHEA-S, LH, FSH, prolactin, TSH, free T4), metabolic markers (HbA1c, fasting insulin, lipid panel, liver enzymes), and a transvaginal ultrasound if appropriate.
Frequently asked questions
What are the symptoms of PMOS?
PMOS symptoms span five pillars: endocrine (high androgens, low SHBG), metabolic (insulin resistance, weight gain at the waist, pre-diabetes, fatty liver), reproductive (irregular periods, infertility, miscarriage risk), dermatological (acne, hirsutism, hair loss, acanthosis nigricans), and mental health (depression, anxiety, eating disorders, sleep issues). Most women have symptoms across three or four pillars.
Are PMOS symptoms the same as PCOS symptoms?
Yes. PMOS is the new name for PCOS as of 12 May 2026. The symptoms are identical. The renaming organised the existing symptom list into five pillars and added explicit recognition of the mental health pillar.
What are the first signs of PMOS?
The earliest signs are usually irregular cycles (longer than 35 days or skipping months), acne along the jawline that persists past adolescence, and unexplained weight gain at the waist. Hirsutism often appears later. Mental health symptoms (especially anxiety and disordered eating) often precede the metabolic symptoms by years and are commonly missed at first assessment.
Can PMOS symptoms come and go?
Yes. PMOS symptoms fluctuate with stress, sleep, diet, weight changes, and life stage. Cycles may briefly normalise during periods of lower stress or after weight loss. Pregnancy can temporarily improve some symptoms. Perimenopause often worsens metabolic symptoms even as androgen-driven symptoms stabilise.
What is the most common symptom of PMOS?
Irregular periods (70 to 90 percent prevalence), followed by hirsutism (around 70 percent), insulin resistance (around 70 percent), high androgens on bloodwork (60 to 80 percent), and acne (around 40 percent). Around 30 percent of women have all four of the dominant symptoms.
Can you have PMOS with no visible symptoms?
Yes. A subset of women have PMOS with no obvious external symptoms (no acne, no hirsutism, regular cycles in some cycles) but still have polycystic ovary morphology on ultrasound and elevated androgens on bloodwork. This is sometimes called "silent" or "phenotype D" PMOS. Metabolic risk still applies and warrants screening.
Are PMOS symptoms worse in some phenotypes?
The severity varies by phenotype. Insulin-resistant PMOS (70 percent of cases) tends to have the most prominent metabolic symptoms. Inflammatory PMOS has the most prominent skin symptoms. Adrenal PMOS tends to have milder weight symptoms but more anxiety and fatigue. Post-pill PMOS typically resolves within 12 to 18 months of stopping hormonal contraceptives.
Why was mental health added as a PMOS symptom pillar?
The 2023 Lancet systematic review of mental health in PCOS found roughly 3x higher rates of depression and 2.5x higher rates of anxiety than the general population. Mental health screening was inconsistent under the PCOS name. PMOS makes mental health one of five recognised symptom pillars and pushes clinicians to screen routinely.
What to read next
- PCOS is now PMOS: the full renaming explainer
- PCOS vs PMOS side by side
- Why was PCOS renamed PMOS
- PMOS diet: what to eat
- Best supplements for PMOS
Map your symptoms to a PMOS phenotype
Most PMOS symptoms cluster by phenotype.
The fastest way to know which symptoms are likely to dominate for you (and which meal plan will move them the most) is the free 90-second phenotype quiz. The result tells you which of the four PMOS phenotypes you fit and what to do about it.
How this article was researched
Sources include the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, the 2023 Lancet systematic review of mental health in PCOS, the 2023 Lancet meta-analysis on PCOS and type 2 diabetes risk, the 2022 Eating Behaviors meta-analysis on disordered eating in PCOS, the 2023 systematic review on non-alcoholic fatty liver disease in PCOS, and the 12 May 2026 PCOS to PMOS renaming consensus paper in The Lancet. Symptom prevalence ranges drawn from large international cohort studies. This article is informational and not medical advice. See our editorial standards.
Community Comments
Add a comment